Skip to main
TRAX

TRAX Stock Forecast & Price Target

TRAX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

First Tracks is expected to see future success with its strong pipeline and targeted and well-researched treatment options for various autoimmune and inflammatory diseases, specifically ANB033. The company's sound financials and ongoing clinical trials, particularly in EoE and other conditions, further support its potential in the market. The FDA's draft guidance and competitive landscape are also favorable indicators for First Tracks' success in the long-term.

Bears say

First Tracks is facing multiple challenges that could impact the success of their pipeline drugs. With no approved drugs and potential regulatory changes, the success of their clinical trials may be at risk. Additionally, there are already approved biologics targeting the same pathways as their drugs in development, making it difficult for them to stand out in the market. Lastly, their pipeline drugs face tough competition from currently available treatments and may not be able to differentiate themselves in terms of efficacy and safety.

TRAX has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About First Tracks Biotherapeutics Inc (TRAX) Forecast

Analysts have given TRAX a Buy based on their latest research and market trends.

According to 6 analysts, TRAX has a Buy consensus rating as of May 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

First Tracks Biotherapeutics Inc (TRAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.